Eupraxia Pharmaceuticals's total assets for Q2 2024 were C$24.98M, a decrease of -31.83% from the previous quarter. EPRX total liabilities were C$11.64M for the fiscal quarter, a -37.19% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.